Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of BKM120 in triple-negative metastatic breast cancer
2011-006083-45Phase 2Completed
- Sponsor
- SOLTI
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in triple-negative breast cancer (TNBC) and breast cancer, sponsored by SOLTI. Primary endpoint: Clinical benefit rate. Started Jan 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2011-006083-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006083-45.